193 related articles for article (PubMed ID: 15605920)
1. Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
Gopal R
J Support Oncol; 2004; 2(6 Suppl 3):13-7. PubMed ID: 15605920
[TBL] [Abstract][Full Text] [Related]
2. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
3. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
[TBL] [Abstract][Full Text] [Related]
6. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
Wynn RB; Mehta V
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
Gopal R
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S55-9. PubMed ID: 16015536
[TBL] [Abstract][Full Text] [Related]
8. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
10. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
[TBL] [Abstract][Full Text] [Related]
15. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.
Mehta V
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):5-24. PubMed ID: 15963660
[TBL] [Abstract][Full Text] [Related]
16. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Rosenman J
Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
[TBL] [Abstract][Full Text] [Related]
17. Radioprotective effect of amifostine in radiation pneumonitis.
Choi NC
Semin Oncol; 2003 Dec; 30(6 Suppl 18):10-7. PubMed ID: 14727236
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
Wang S; Liao Z; Wei X; Liu HH; Tucker SL; Hu CS; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1399-407. PubMed ID: 16997503
[TBL] [Abstract][Full Text] [Related]
19. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S105-8. PubMed ID: 16015544
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]